Stocktoria
Actinium Pharmaceuticals, Inc. ATNM
Actinium Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90,000 | — | $81,000 | $1.0M | $1.1M | — | — | — | — | — |
| R&D expense | $21.1M | $30.0M | $38.7M | $23.1M | $18.0M | $16.1M | $16.6M | $17.1M | $17.7M | $17.8M |
| Operating income | -$36.2M | -$42.1M | -$51.9M | -$34.1M | -$25.0M | -$22.4M | -$22.1M | -$23.8M | -$26.9M | -$26.8M |
| Interest expense | — | — | — | — | — | — | — | — | — | $5,007 |
| Net income | -$33.9M | -$38.2M | -$48.8M | -$33.0M | -$24.8M | -$22.2M | -$21.9M | -$23.7M | -$26.6M | -$24.3M |
| EPS (diluted) | $-1.09 | $-1.27 | $-1.83 | $-1.37 | $-1.20 | — | — | — | — | — |
| Operating cash flow | -$24.6M | -$33.1M | -$47.3M | $8.6M | -$20.9M | -$21.6M | -$21.5M | -$20.6M | -$21.6M | -$20.8M |
| Free cash flow | -$24.7M | -$33.1M | -$47.5M | $8.3M | -$21.0M | -$21.9M | -$21.5M | -$20.7M | -$21.6M | -$20.8M |
| Cash & equivalents | $48.0M | $72.9M | $76.7M | $108.9M | $77.8M | $63.6M | $9.3M | $13.7M | $17.4M | $20.5M |
| Total assets | $51.8M | $76.9M | $81.4M | $114.2M | $80.4M | $66.4M | $11.7M | $14.9M | $18.3M | $22.5M |
| Total liabilities | $43.9M | $44.1M | $45.1M | $47.7M | $6.8M | $5.1M | $6.0M | $6.1M | $4.7M | $4.5M |
| Shareholders' equity | $7.8M | $32.8M | $36.4M | $66.5M | $73.5M | $61.3M | $5.6M | $8.8M | $13.7M | $18.0M |
Growth · year-over-year · Revenue CAGR -57.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | -92.1% | -10.0% | — | — | — | — | — | — |
| Free cash flow growth | — | — | -673.7% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.